NI201500087A - Formulación farmacéutica de n-[5-[2-(3-,5-dimetoxifenil)etil]-2h-pirazol-3-il]-4-[(3r, 5s)-3, 5 - dimetl piperazin - 1 il] benzamida - Google Patents
Formulación farmacéutica de n-[5-[2-(3-,5-dimetoxifenil)etil]-2h-pirazol-3-il]-4-[(3r, 5s)-3, 5 - dimetl piperazin - 1 il] benzamidaInfo
- Publication number
- NI201500087A NI201500087A NI201500087A NI201500087A NI201500087A NI 201500087 A NI201500087 A NI 201500087A NI 201500087 A NI201500087 A NI 201500087A NI 201500087 A NI201500087 A NI 201500087A NI 201500087 A NI201500087 A NI 201500087A
- Authority
- NI
- Nicaragua
- Prior art keywords
- dimetoxifenil
- dimetl
- pirazol
- etil
- piperazin
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 title 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se proporcionan composiciones farmacéuticas que comprenden un compuesto de Fórmula (I), según se define en la presente, y una cantidad de un agente efervescente alcalino que sea suficiente para proporcionar una disolución satisfactoria in vitro; y que comprenden además uno o más ingredientes farmacéuticamente aceptables; y procesos para obtenerlas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261740520P | 2012-12-21 | 2012-12-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
NI201500087A true NI201500087A (es) | 2016-02-16 |
Family
ID=49998566
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NI201500087A NI201500087A (es) | 2012-12-21 | 2015-06-18 | Formulación farmacéutica de n-[5-[2-(3-,5-dimetoxifenil)etil]-2h-pirazol-3-il]-4-[(3r, 5s)-3, 5 - dimetl piperazin - 1 il] benzamida |
Country Status (26)
Country | Link |
---|---|
US (2) | US20140179712A1 (es) |
EP (1) | EP2934494B1 (es) |
JP (1) | JP6328138B2 (es) |
KR (1) | KR20150096787A (es) |
CN (1) | CN104853750B (es) |
AR (1) | AR094203A1 (es) |
AU (1) | AU2013366023B2 (es) |
BR (1) | BR112015014200A2 (es) |
CA (1) | CA2893480C (es) |
CL (1) | CL2015001786A1 (es) |
CR (1) | CR20150320A (es) |
DO (1) | DOP2015000127A (es) |
ES (1) | ES2742400T3 (es) |
HK (1) | HK1212229A1 (es) |
IL (1) | IL239521A0 (es) |
MX (1) | MX368670B (es) |
NI (1) | NI201500087A (es) |
PE (1) | PE20151418A1 (es) |
PH (1) | PH12015501389A1 (es) |
RU (1) | RU2674978C2 (es) |
SG (1) | SG11201504769WA (es) |
TW (1) | TWI651085B (es) |
UA (1) | UA115342C2 (es) |
UY (1) | UY35244A (es) |
WO (1) | WO2014096828A1 (es) |
ZA (1) | ZA201505197B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140179712A1 (en) | 2012-12-21 | 2014-06-26 | Astrazeneca Ab | Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide |
WO2024031226A1 (zh) * | 2022-08-08 | 2024-02-15 | 无锡和誉生物医药科技有限公司 | Fgfr抑制剂的药物组合物、多晶型物及其在药学上的应用 |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB843940A (en) | 1955-09-27 | 1960-08-10 | Kodak Ltd | Method of processing photographic silver halide emulsions containing colour couplers |
BE667399A (es) | 1964-07-30 | 1965-11-16 | ||
JPS57150846A (en) | 1981-03-13 | 1982-09-17 | Konishiroku Photo Ind Co Ltd | Photographic element |
JPS63133152A (ja) | 1986-11-26 | 1988-06-04 | Konica Corp | 新規なマゼンタカプラ−を含有するハロゲン化銀写真感光材料 |
JPH0467645A (ja) | 1990-07-09 | 1992-03-03 | Nec Kyushu Ltd | バーンイン装置 |
US5292520A (en) * | 1990-09-13 | 1994-03-08 | Akzo N.V. | Stabilized solid pharmaceutical composition containing acid addition salts of a basic drug and an alkaline stabilizer |
JP2890065B2 (ja) | 1990-11-10 | 1999-05-10 | コニカ株式会社 | ハロゲン化銀写真感光材料 |
JPH04184437A (ja) | 1990-11-20 | 1992-07-01 | Fuji Photo Film Co Ltd | カラー画像形成方法及びハロゲン化銀カラー写真感光材料 |
JPH04292322A (ja) | 1991-03-19 | 1992-10-16 | Fujitsu Ltd | ラック給排装置 |
JPH0511414A (ja) | 1991-07-02 | 1993-01-22 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
AU664392B2 (en) | 1991-10-18 | 1995-11-16 | Monsanto Technology Llc | Fungicides for the control of take-all disease of plants |
BR9305466A (pt) | 1992-03-26 | 1994-12-20 | Dowelanco | Nitroanilinas n-heterocíclicas usadas como fungicidas |
HRP921338B1 (en) | 1992-10-02 | 2002-04-30 | Monsanto Co | Fungicides for the control of take-all disease of plants |
TW240217B (es) | 1992-12-30 | 1995-02-11 | Glaxo Group Ltd | |
JP3156026B2 (ja) | 1993-12-27 | 2001-04-16 | 株式会社大塚製薬工場 | ホスホン酸ジエステル誘導体 |
CN1165482A (zh) | 1994-11-10 | 1997-11-19 | 科西雷佩蒂斯公司 | 用作蛋白激酶抑制剂的吡唑药物组合物 |
FR2745500B1 (fr) | 1996-03-04 | 1998-04-03 | Synthelabo | Formulations pharmaceutiques a liberation prolongee contenant de la mizolastine |
CA2275796A1 (en) | 1996-12-23 | 1998-07-02 | Donald Joseph Phillip Pinto | Nitrogen containing heteroaromatics as factor xa inhibitors |
WO1998052944A1 (en) | 1997-05-19 | 1998-11-26 | Sugen, Inc. | Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders |
AU7726898A (en) | 1997-05-22 | 1998-12-11 | G.D. Searle & Co. | Pyrazole derivatives as p38 kinase inhibitors |
US6271237B1 (en) | 1997-12-22 | 2001-08-07 | Dupont Pharmaceuticals Company | Nitrogen containing heteromatics with ortho-substituted P1s as factor Xa inhabitors |
JP3310226B2 (ja) | 1998-10-16 | 2002-08-05 | 松下電器産業株式会社 | 音声合成方法および装置 |
GB9823103D0 (en) | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
ATE286026T1 (de) | 1999-02-10 | 2005-01-15 | Mitsubishi Pharma Corp | Amid-derivate und deren medizinische verwendung |
WO2000049001A2 (en) | 1999-02-16 | 2000-08-24 | E.I. Du Pont De Nemours And Company | Phenoxy-, phenylthio-, phenylamino-, benzyloxy-, benzylthio- or benzylaminopyrimidine insectidices and acaricides |
ATE305782T1 (de) | 1999-08-12 | 2005-10-15 | Pharmacia Italia Spa | 3(5)-amino-pyrazolderivate, deren herstellungsverfahren und verwendung als krebshemmende mittel |
BR0013551A (pt) | 1999-08-13 | 2003-06-17 | Vertex Pharma | Inibidores de cinases n-terminal cjun (jnk) e outras cinases de proteìnas |
AU771460B2 (en) | 1999-09-24 | 2004-03-25 | Smithkline Beecham Corporation | Thrombopoietin mimetics |
US20050209297A1 (en) | 2000-08-31 | 2005-09-22 | Pfizer Inc | Pyrazole derivatives |
US20040043904A1 (en) | 2000-09-22 | 2004-03-04 | Hiroshi Yamaguchi | N-(4-pyrazolyl) amide derivatives, chemicals for agricultural and horticultural use, and usage of the same |
EP1352650B1 (en) | 2000-12-18 | 2012-03-07 | Institute of Medicinal Molecular Design, Inc. | Inhibitors against the production and release of inflammatory cytokines |
US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
JP2004538266A (ja) | 2001-04-27 | 2004-12-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | ピラゾール由来のキナーゼインヒビター |
IS1935B (is) * | 2002-03-19 | 2004-06-16 | Actavis Group Hf. | Fósínópríl lyfjasamsetning |
EA008769B1 (ru) | 2002-06-05 | 2007-08-31 | Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. | Лекарственное средство для лечения диабета |
EP1510210A4 (en) | 2002-06-05 | 2009-01-07 | Inst Med Molecular Design Inc | IMMUNITY-CONTAINING PROTEIN KINASE HEMMER |
EP1514544A4 (en) | 2002-06-06 | 2009-01-07 | Inst Med Molecular Design Inc | HYPO-ALLERGENIC |
AU2003252478A1 (en) | 2002-07-10 | 2004-02-02 | Ono Pharmaceutical Co., Ltd. | Ccr4 antagonist and medicinal use thereof |
US7176198B2 (en) | 2002-08-01 | 2007-02-13 | Pfizer Inc. | 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease |
DE602004028907D1 (de) | 2003-02-06 | 2010-10-14 | Bristol Myers Squibb Co | Als kinaseinhibitoren geeignete verbindungen auf thiazolylbasis |
BRPI0409949A (pt) | 2003-05-01 | 2006-04-25 | Bristol Myers Squibb Co | compostos de pirazol amida aril-substituìda úteis como inibidores de cinase |
US20040220170A1 (en) | 2003-05-01 | 2004-11-04 | Atkinson Robert N. | Pyrazole-amides and sulfonamides as sodium channel modulators |
US7115359B2 (en) | 2003-07-25 | 2006-10-03 | Konica Minolta Medical & Graphic, Inc. | Photothermographic material |
AU2004268948A1 (en) | 2003-08-21 | 2005-03-10 | Osi Pharmaceuticals, Inc. | N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors |
US7432271B2 (en) | 2003-09-02 | 2008-10-07 | Bristol-Myers Squibb Company | Pyrazolyl inhibitors of 15-lipoxygenase |
US20050171172A1 (en) | 2003-11-13 | 2005-08-04 | Ambit Biosciences Corporation | Amide derivatives as PDGFR modulators |
US7671072B2 (en) | 2003-11-26 | 2010-03-02 | Pfizer Inc. | Aminopyrazole derivatives as GSK-3 inhibitors |
US7652146B2 (en) | 2004-02-06 | 2010-01-26 | Bristol-Myers Squibb Company | Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors |
GB2411355B (en) * | 2004-02-27 | 2006-02-22 | Niche Generics Ltd | Pharmaceutical composition |
US7253204B2 (en) | 2004-03-26 | 2007-08-07 | Methylgene Inc. | Inhibitors of histone deacetylase |
EP1751133B1 (en) | 2004-04-28 | 2010-04-14 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of rock and other protein kinases |
JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
RU2008107868A (ru) | 2005-08-02 | 2009-09-10 | Айрм Ллк (Bm) | Соединения и композиции в качестве ингибиторов протеинкиназ |
EP1945190A1 (en) * | 2005-09-22 | 2008-07-23 | Swissco Devcelopment AG | Effervescent metformin composition and tablets and granules made therefrom |
IS2385B (is) * | 2006-02-10 | 2008-07-15 | Actavis Group Hf. | Klópidógrel bísúlfat lyfjasamsetningar |
US7737149B2 (en) * | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
PL386051A1 (pl) * | 2008-09-09 | 2010-03-15 | Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna | Stabilna doustna kompozycja farmaceutyczna zawierająca farmaceutycznie dopuszczalną sól kwsu [(E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo] (3R,5S)-3,5-dihydroksyhept-6-enowego |
EA201171282A1 (ru) * | 2009-04-24 | 2012-05-30 | Айсьютика Пти Лтд. | Способ производства коммерческих порошков, содержащих нано- и микрочастицы |
BRPI1009367A2 (pt) * | 2009-05-27 | 2016-03-08 | Dasan Medichem Co Ltd | tablete de camada múltipla |
JP2013501810A (ja) * | 2009-08-12 | 2013-01-17 | ヴァリーント インターナショナル(バルバドス)エスアールエル | 医薬組成物 |
WO2012052757A1 (en) * | 2010-10-20 | 2012-04-26 | Astrazeneca Ab | Tumour phenotype patient selection method |
US20140179712A1 (en) | 2012-12-21 | 2014-06-26 | Astrazeneca Ab | Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide |
-
2013
- 2013-12-17 US US14/108,595 patent/US20140179712A1/en not_active Abandoned
- 2013-12-19 WO PCT/GB2013/053356 patent/WO2014096828A1/en active Application Filing
- 2013-12-19 SG SG11201504769WA patent/SG11201504769WA/en unknown
- 2013-12-19 PE PE2015001038A patent/PE20151418A1/es not_active Application Discontinuation
- 2013-12-19 AR ARP130104937A patent/AR094203A1/es unknown
- 2013-12-19 AU AU2013366023A patent/AU2013366023B2/en active Active
- 2013-12-19 CA CA2893480A patent/CA2893480C/en active Active
- 2013-12-19 EP EP13821906.8A patent/EP2934494B1/en active Active
- 2013-12-19 BR BR112015014200A patent/BR112015014200A2/pt not_active IP Right Cessation
- 2013-12-19 KR KR1020157019620A patent/KR20150096787A/ko not_active Application Discontinuation
- 2013-12-19 ES ES13821906T patent/ES2742400T3/es active Active
- 2013-12-19 RU RU2015126345A patent/RU2674978C2/ru active
- 2013-12-19 UA UAA201506048A patent/UA115342C2/uk unknown
- 2013-12-19 CN CN201380065855.6A patent/CN104853750B/zh active Active
- 2013-12-19 MX MX2015008067A patent/MX368670B/es active IP Right Grant
- 2013-12-19 JP JP2015548757A patent/JP6328138B2/ja active Active
- 2013-12-20 TW TW102147616A patent/TWI651085B/zh active
- 2013-12-23 UY UY0001035244A patent/UY35244A/es not_active Application Discontinuation
-
2015
- 2015-05-27 DO DO2015000127A patent/DOP2015000127A/es unknown
- 2015-06-17 CR CR20150320A patent/CR20150320A/es unknown
- 2015-06-17 PH PH12015501389A patent/PH12015501389A1/en unknown
- 2015-06-18 IL IL239521A patent/IL239521A0/en unknown
- 2015-06-18 NI NI201500087A patent/NI201500087A/es unknown
- 2015-06-19 CL CL2015001786A patent/CL2015001786A1/es unknown
- 2015-07-20 ZA ZA2015/05197A patent/ZA201505197B/en unknown
-
2016
- 2016-01-12 HK HK16100256.1A patent/HK1212229A1/xx unknown
- 2016-06-15 US US15/183,088 patent/US10420764B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR117001A2 (es) | Formulación de premezcla de dexmedetomidina | |
CR20210108A (es) | Benzamidas sustituidas con 1, 3-tiazol-2-ilo | |
NI201500142A (es) | Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos. | |
HN2011003072A (es) | Sales de disacarina, ácido difumárico, ácido d1-1-hidroxi-2-naftoico y ácido monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino)pirimidin-5-il)metil)fenil)acetato de 4-(demitilamino)butilo | |
PH12015501082A1 (en) | Pyridine -2-amides useful as cb2 agonists | |
ECSP109917A (es) | Nuevos derivados de ácido azabifenilaminobenzoico | |
PE20150200A1 (es) | Formulacion de anticuerpos | |
BR112014016550A2 (pt) | formulação de liberação retardada para reduzir a frequência de urinação e método de uso da mesma | |
PE20140255A1 (es) | Tableta dispersable en forma oral | |
BR112014016661A8 (pt) | formulação de liberação prolongada para reduzir a frequência de urinação e método de uso da mesma | |
BR112014020113A8 (pt) | Composições farmacêuticas e método para diminuir a frequência de micção | |
UY31788A (es) | Formulación farmacéutica sólida con liberación retardada | |
BR112013019394A2 (pt) | uso de um agente | |
SV2012004203A (es) | Nueva asociación entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un inhibidor de la acetilcolinesterasa y las composiciones farmacéuticas que la contienen | |
BR112015010271A8 (pt) | produto de comicronização, processo para o preparo de um produto de comicronização, composição farmacêutica e seus usos | |
CO6592109A2 (es) | Nueva forma cristalina de un derivado de ciclopropilbenzamida | |
EA201490573A1 (ru) | Соединение бензотиазолона | |
NI201500087A (es) | Formulación farmacéutica de n-[5-[2-(3-,5-dimetoxifenil)etil]-2h-pirazol-3-il]-4-[(3r, 5s)-3, 5 - dimetl piperazin - 1 il] benzamida | |
TR201901792T4 (tr) | Yeni (trimetoksifenilamino)pirimidinil formülasyonları. | |
PE20160285A1 (es) | Profarmacos de rebamipida novedosos, metodo de preparacion y uso de los mismos. | |
CR20120461A (es) | Hidrato del hidrobromuro de agomelatina y preparación de éste | |
ECSP12012332A (es) | Asociación de inhibidores de la xantina oxidasa y la instatina y su uso | |
IN2014DN07897A (es) | ||
MA33055B1 (fr) | Nouvelle combinaison de principes actifs contenant un anti-inflammatoire non steroidien et un derive de colchicoside | |
CR20120618A (es) | Asociación de inhibidores de la xantina oxidasa y la instatina y su uso |